as	of	May	21.	2019

	A(H1N1)pdm09						A(H3N2)					В					
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	5 ^a (1.7%)	14 ^b (0.8%)	14 ^b (0.8%)	0	0	188 (100%)	28° (9.5%)	0	0	0	0	155 (100%)	0	0	0	0	0
Number of viruses tested	296	1,762	1,762	282	282	188	296	195	195	195	195	155	36	58	58	58	58
Number of viruses reported	2,737					3,950					213						

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

^a Patients without treatment 0

^b Patients without treatment 2

^c Patients without treatment 3